Covid-19 roundup: Mod­er­na show­cas­es progress on its bi­va­lent boost­er; No­vavax wins ap­proval in Japan

New da­ta from Mod­er­na of­fer en­cour­ag­ing re­sults for the mR­NA pow­er­house’s bi­va­lent boost­er can­di­date.

The bi­va­lent boost­er can­di­date, known as mR­NA-1273.211 and which in­cludes mu­ta­tions found in the Be­ta vari­ant of con­cern, best­ed the com­pa­ny’s orig­i­nal boost­er in terms of neu­tral­iz­ing titers against all vari­ants of con­cern, in­clud­ing Omi­cron.

The news, which fol­lows sim­i­lar re­sults for the Pfiz­er/BioN­Tech Covid-19 vac­cine when com­bined with Be­ta, bodes well for the boost­er in the fall.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER